Medicine Description tasigna 200mg
Tasigna 200mg Capsule is a medication that functions as a selective tyrosine kinase inhibitor specifically targeting the BCR-ABL fusion protein. This fusion protein is a result of the Philadelphia chromosome translocation, which plays a pivotal role in the pathogenesis of chronic myeloid leukemia (CML). By binding to the ATP-binding site of the BCR-ABL protein with a higher affinity than imatinib, Tasigna effectively inhibits the tyrosine kinase activity, which is essential for the proliferation and survival of leukemic cells. This inhibition disrupts downstream signaling pathways that promote cell growth and division. Consequently, Tasigna not only helps to overcome resistance mutations that may arise with other therapies but also exerts its effects on the leukemic clone, leading to a reduction in disease burden and improvement in patient outcomes.
Indications and Uses of Tasigna 200mg Capsule
- Chronic Myeloid Leukemia (CML) in chronic phase
- Chronic Myeloid Leukemia (CML) in accelerated phase
- Chronic Myeloid Leukemia (CML) in blast phase
- Potential use in patients with resistance or intolerance to previous therapies
Side Effects of Tasigna 200mg Capsule
- Fatigue
- Nausea
- Headache
- Rash
- Diarrhea
- Abdominal pain
- Increased liver enzymes
- Peripheral edema
Storage and Handling
Store Tasigna 200mg Capsules at room temperature, away from moisture and direct light. Keep the medication out of reach of children and do not use past the expiration date indicated on the packaging.
Patient Advice and Precautions
Patients should be advised to take Tasigna on an empty stomach, at least 2 hours after a meal and 1 hour before the next meal. Regular monitoring of blood counts and liver function is important during therapy. Patients should be educated about potential interactions with other medications and the importance of adherence to prescribed therapy. Consult healthcare providers for any side effects that persist or worsen.